|Videos|June 16, 2017

Can New Antimalarials Be a Gamechanger in Endemic Countries?

Jeremy Burrows, DPhil, MA, explains how new antimalarials could change the game for countries where malaria is endemic.

Jeremy Burrows, DPhil, MA, Vice President, Head of Discovery, Medicines for Malaria Venture, Switzerland, explains how new antimalarials could change the game for countries where malaria is endemic.

Interview Transcript (slightly modified for readability)

“In the countries where malaria is endemic, these new treatment options are still incredibly important. First, because they will provide the treatment options of the future when the existing drugs fail because of resistance. Secondly, we have this ambition for elimination, eradication, and these new drugs, which are coming through the pipeline we hope will deliver the tools that will actually enable us to do that.”


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.